Introduction
Smoking is associated with considerable mortality and morbidity. 1 Smoking accounts for >5 million premature deaths worldwide each year, 2 including >480,000 in the US alone. 3, 4 It also causes a wide range of chronic diseases and cancers, which place a considerable burden on health care systems. 1 Strategies for smoking cessation are important for reducing the overall smoking burden 4 and have proved to be effective. 5 Between 2005 and 2014, the prevalence of cigarette smoking among US adults decreased from 20.9% to 16.8%. 3 Smokers' interest in quitting smoking is high: in 2015, 68.0% of current US adult daily smokers reported that they wanted to stop smoking, 6 and an estimated 55.4% of all smokers had attempted to quit during the past year. 6 The current clinical practice guidelines recommend that a combination of medication and counseling is most effective for obtaining cessation. 4, 5, 7 Smoking cessation medications include nicotine replacement therapy (NRT), available both over the counter and on prescription depending on formulation, and bupropion (Zyban®; GlaxoSmithKline plc, London, UK) and varenicline (Champix®; Pfizer, Inc., New York, NY, USA), both available by prescription only.
The Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES), the largest clinical trial of smoking cessation pharmacotherapies to date, adopted a double-blind, triple-dummy design to compare the efficacy and neuropsychiatric safety profile of varenicline, bupropion, NRT patch, and placebo in smokers with and without psychiatric disorders. 8 The study, conducted at 140 centers in 16 countries between 2011 and 2015, comprised a 12-week treatment phase and a 12-week follow-up period. 8 Study participants were randomized to treatment, with stratification into nonpsychiatric and psychiatric cohorts. The primary efficacy end point was continuous smoking abstinence for Weeks 9-12, and a secondary efficacy end point was continuous abstinence for Weeks 9-24. 8 Study results indicated that, for these primary and secondary end points, varenicline was more effective than bupropion, NRT patch, and placebo, and bupropion and NRT patch were more effective than placebo. 8 The cost-effectiveness of smoking cessation interventions has been previously shown in several studies. 5, [9] [10] [11] [12] Varenicline, specifically, has been shown to be cost-effective in the US health care setting using the Benefits of Smoking Cessation on Outcomes (BENESCO) model, a Markov model developed to simulate the lifetime direct costs and consequences of a single quit attempt in a hypothetical cohort of US adult smokers. 13 In light of the new comparative efficacy data from the EAGLES trial and the decreasing prevalence of smoking in the US population, the objective of this study was to update the inputs of the BENESCO model to investigate long-term health and economic outcomes of smoking cessation treatment using varenicline, bupropion, NRT patch, and placebo.
Methods

The BENESCO model
The BENESCO model was initially developed to assess the cost-effectiveness of a single smoking cessation attempt in a hypothetical cohort of US adult smokers using varenicline, bupropion, NRT, or unaided cessation. 13 Designed as a Markov model, the impact of a single attempt in the first year on the incidence of smoking-related mortality and morbidity is estimated in 1-year cycles running up to a lifetime, which is set at 99 years of age, after which subjects remaining in the model will die in the next cycle due to all-cause mortality. 13 This requirement ensures that all patients in the model will experience mortality through the duration of the simulation. Never and former smokers are excluded from the simulation because the initial cohort focuses on current smokers attempting to quit. 13 The model includes health states corresponding to chronic obstructive lung disease (COPD), lung cancer, coronary heart disease (CHD), and stroke, in order to simulate the epidemiological pattern of the most prevalent and costly of the smokingrelated conditions. 13 The transition probabilities of subjects between these health states are derived from three factors: 1) smoking status, including initial quit rate and subsequent short-or long-term relapse rates; 2) morbidity status, derived from the relative risk of developing one of the four smokingrelated morbidities; and 3) risk of mortality. 13 At the conclusion of each cycle, subjects stay in the same state, undergo transition to another morbidity state, or die from one of the included morbidities or another cause (all-cause mortality).
In the present study, prevalence, incidence, mortality, direct treatment costs of smoking-related conditions, and the efficacy and costs of the smoking cessation interventions have been updated based on the current literature. Smoking-related disease health utilities and risks of these diseases relative to nonsmokers were assumed to remain unchanged over time, as previously reported. 14 The BENESCO model takes the perspective of the US health care system.
BENESCO model updates
Several data updates were included in this analysis to modernize our study from the initial cost-effectiveness analyses published by Howard et al. 13 The efficacy estimates used in the BENESCO model were updated to reflect comparative head-to-head data arising from the EAGLES trial. 8 However, these efficacy estimates required adjustments for use within the BENESCO framework for two reasons: 1) the EAGLES trial provided efficacy end points separately for the psychiatric and nonpsychiatric populations, whereas the BENESCO model does not differentiate between the two populations, and 2) the EAGLES trial measured continuous abstinence from Week 9 to Week 24, whereas the BENESCO model uses a 52-week cycle.
The first adjustment to derive the quit rates used in the model addressed the subpopulation distribution. The 
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Cost-effectiveness of varenicline for smoking cessation EAGLES trial comprised two cohorts stratified by psychiatric history: 4,000 subjects with and 4,000 without a history of psychiatric disorders. Subjects with a history of psychiatric disorders were defined as having at least one of the following Axis I or II diagnoses: psychotic disorders (schizophrenia and schizoaffective disorder), mood disorders (major depression and bipolar I and II disorders), anxiety disorders (panic disorder with or without agoraphobia), posttraumatic stress disorder, obsessive-compulsive disorder, social phobia, generalized anxiety disorder, and a past history of borderline personality disorder. Due to the equal sampling between the two cohorts, subjects with psychiatric history were over represented in the EAGLES trial. Therefore, to obtain a single quit rate which represents the distribution of psychiatric comorbidities in the general population, a literature search was conducted, and a study reporting that 29.2% of the general population was diagnosed with these conditions was identified. 15 For each treatment group, the Weeks 9-24 efficacy end points from the two cohorts were pooled using a weighted average to obtain a single Weeks 9-24 quit rate representative of the distribution of psychiatric disorders in the general population (Table 1) . After pooling, the Weeks 9-24 continuous abstinence rates for each treatment group were again adjusted to approximate a 1-year quit rate by applying the weighted average of the ratios of the Week 52 and Week 24 quit rates for varenicline, bupropion, and placebo from an analysis by Nides et al. 16 Thus, the effectiveness of a single quit attempt for each treatment ultimately used in this study was calculated based on the Weeks 9-24 end points from EAGLES, 8 pooled with data about the prevalence of psychiatric disorders in the general population, 15 and extended to 52 weeks using the average abstinence ratio. 16 The quit rates used in this updated model are shown in Table 1 .
Additional updates to the data inputs, as previously mentioned, focused on providing newer data for the epidemiology of smoking in the US population, the epidemiology and direct treatment costs of the four smoking-related conditions included in the model, and the costs of the smoking cessation interventions. The US population figures and allcause mortality rates were identified from the US Census Bureau. 17, 18 The demographic breakdown of smokers included in the study cohort was estimated from Centers for Disease Control and Prevention (CDC) reports (Table 2) : Current Cigarette Smoking Among Adults in the US 3 and Summary Health Statistics for US Adults. 19 Prevalence, incidence, and mortality rates of COPD, 20, 21 lung cancer, 17, 22 CHD, 20, 23 and stroke 17, 18, 20, [23] [24] [25] were identified through literature searches that included reports from the American Heart Association, the CDC, and peer-reviewed publications.
Disease management and intervention costs were updated for each smoking-related disease and were inflated as necessary to reflect 2014 US costs by applying Medical Care Consumer Price Indexes (Table 3) . [26] [27] [28] [29] The treatment costs of varenicline, bupropion, and NRT patch were defined based on the average Wholesale Acquisition Cost unit price sourced from the First DataBank's FDB MedKnowledge data, as of June 1, 2014, and the recommended course for smoking cessation. 30 
Updated model data analysis
After updating the BENESCO inputs as described earlier, the model was run for an entry population of 18,394,068 smokers to compare varenicline, bupropion, NRT patch, and placebo with regard to the incidence of smoking-related morbidity, the incidence of smoking-related mortality, and cost-effectiveness with a time horizon from 2 years to lifetime. A default discount rate of 3% was used for costs and outcomes. The lifetime horizon was regarded as capturing all the costs and benefits resulting from smoking and smoking cessation. A probabilistic sensitivity analysis (PSA) was conducted with 1,000 iterations at the lifetime time horizon for each pair-wise comparison of smoking cessation strategies, resulting in cost-effectiveness acceptability curves and costeffectiveness planes.
Results
The updated BENESCO model showed that, as expected, the cumulative incidence of COPD, lung cancer, CHD, and stroke at the lifetime horizon varied according to treatment efficacy, with varenicline having the lowest cumulative incidence of these conditions and placebo having the highest (Table 4) . For varenicline, there were an estimated 319,730 fewer smoking-related morbidities over the lifetime compared with placebo. Compared with bupropion and NRT, use of varenicline resulted in 175,998 and 166,156 fewer smoking-related morbidities over the lifetime, respectively (Table 4) . A similar trend was observed at other time horizons.
Similarly, the cumulative incidence of smoking-related deaths from these conditions recorded at each time horizon was also lowest with varenicline and highest with placebo (Table 5) . At a lifetime horizon, smoking-related mortality rates decreased by 198,240 patients with varenicline compared with placebo (bupropion, 109,123; NRT patch, 103,021). Compared with bupropion and NRT patch, treatment with varenicline resulted in 89,117 and 95,219 fewer deaths, respectively.
Annual treatment-related costs were higher for varenicline than for the other comparators at the time horizons of 2, 5, and 10 years (Table 6 ). At these time horizons, varenicline, bupropion, and NRT patch were all more expensive than placebo. At the 20-year horizon, treatment-related costs were lower for varenicline than for NRT patch. At the lifetime horizon, total costs (including costs of interventions and smoking-related conditions) were lower for varenicline than for bupropion or NRT patch, and both varenicline and bupropion had considerably lower total costs than NRT patch and placebo. At all time horizons, quality-adjusted life years (QALYs) gained was greatest for varenicline, followed by bupropion, NRT patch, and placebo ( Table 6 ). As a result of these data, at the lifetime horizon, varenicline dominated all comparator strategies, being more effective and less costly overall, while bupropion dominated NRT patch and placebo, and NRT patch dominated placebo (Table 7) .
For each pairwise treatment comparison, a PSA based on 1,000 simulations resulted in the median estimated incremental cost-effectiveness ratio (ICER) changing by <0.1% for each additional simulation, indicating that the aggregate results were stable. From the PSAs conducted for varenicline versus each comparator at the lifetime horizon, greatest uncertainty in cost-effectiveness was observed for varenicline versus bupropion and varenicline versus NRT patch (data not shown). In all pairwise treatment comparisons, both costs and QALYs were consistently in favor of varenicline across the majority of PSA iterations. As a result, the probability of varenicline being a cost-effective strategy compared to placebo and NRT approached 100% and compared to bupropion 85% beyond the $10,000/QALY threshold.
Discussion
The aim of this study was to undertake an updated costeffectiveness analysis, using current epidemiology inputs The cost of placebo was set at zero. Abbreviations: CHD, chronic heart disease; COPD, chronic obstructive pulmonary disease; NRT, nicotine replacement therapy.
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Cost-effectiveness of varenicline for smoking cessation Abbreviations: BENESCO, Benefits of Smoking Cessation on Outcomes; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; NRT, nicotine replacement therapy. The results of this present cost-effectiveness analysis indicate that smoking cessation provides good value for money. Compared with bupropion or NRT patch, varenicline, the most efficacious pharmacotherapy, appears to prevent the greatest number of cases of smoking-related disease and death while providing a long-term economic benefit. The results demonstrate that varenicline is dominant, ie, less costly and more effective, at the lifetime horizon vs bupropion, NRT, and placebo. These cost-effectiveness results are comparable with the results originally published by Howard et al 13 10 years earlier.
The population estimates reflecting the proportion of US adult smokers who make an attempt to quit reflect the trend toward a decreased smoking prevalence in the US in the past few years, as well as the changed prevalence of smokingrelated disease. 3 Based on the lifetime results, the number needed to treat (NNT) to prevent one smoking-related death was estimated to be 93 for varenicline, 169 for bupropion, and 179 for NRT patch. Similarly, the NNT to prevent one case of smoking-related morbidity was estimated to be 58 for varenicline, 105 for bupropion, and 111 for NRT patch.
A key strength of this study is that it is the first to present cost-effectiveness analyses of all three smoking cessation treatments using data obtained from EAGLES, the largest head-to-head study of varenicline, bupropion, and NRT patch. Additionally, the data inputs were updated to reflect the changing landscape of smoker demographics and epidemiology of smoking-related disease over the past decade. Finally, the study population was more representative of the general population with the inclusion of patients having a psychiatric history, in comparison with the study population from previous clinical trials in which these patients were excluded by design.
A limitation of this study is that pooling was required to consolidate the efficacy values of the two subpopulations for each intervention. Unfortunately, there was no identified published study of the distribution of psychiatric diagnoses in the current smoker population, and thus, prevalence of psychiatric diagnoses in the general population was used. While the magnitude of the prevalence of psychiatric diagnosis in the general population may be debated, a recently published meta-analysis was used. 15 Furthermore, the model also had to project efficacy to 52 weeks from the 24-week data that were available. Since relapse after quitting is essentially independent of the method of quitting, a ratio of the 24-and 52-week data weighted from the Nides et al 16 study provided a reasonable 6-month relapse rate. Additionally, the study design utilized in the Nides et al 16 study was comparable with the EAGLES study design and included three of the four EAGLES treatment arms (varenicline, bupropion, and placebo).
Additional limitations inherent in the methodology included the absence of indirect costs, such as lost productivity, the effects of each pharmacotherapy on the costs of other treatments, and the potential increased costs of health care for former smokers over their assumed longer life span versus smokers. Furthermore, the model structure captures only four disease states and allows for only one morbidity at any given cycle, which is an over simplification of the true clinical impact of smoking. However, this assumption is conservative, and likely the economic results are therefore an underestimate of the true impact of smoking cessation. An area of future research would be in further refining the efficacy of smoking cessation and associated cost implications by age groups to understand the implications of smoking cessation across different age ranges and in conducting a study on the impact of retreatment with varenicline following an unsuccessful first attempt in the US setting.
Conclusion
This study, an update to the original varenicline cost-effectiveness study published by Howard et al, 31 demonstrated consistency in the findings that a single quit attempt with varenicline is less costly and more effective than other smoking cessation pharmacotherapies at the lifetime despite changing smoker demographics, epidemiology of smoking-related disease, and varying costs over the past decade. 
